Nutex Health Inc. (NUTX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Nutex Health Inc. is a physician-led healthcare services company operating 27 hospital facilities across 12 states and a population health management division. The company operates as an out-of-network provider, heavily reliant on the Independent Dispute Resolution (IDR) process under the No Surprises Act for reimbursement.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenue | $210,752 | $243,985 | $427,237 | $455,774 |
| Net Income (Attributable to Nutex) | $65,842 | $(17,697) | $112,649 | $3,520 |
| Diluted EPS | $9.38 | $(2.95) | $15.87 | $0.55 |
| Operating Income | $121,718 | $33,679 | $202,983 | $114,340 |
| Adjusted EBITDA | $89,985 | $71,614 | $147,549 | $144,435 |
| Cash and Equivalents | $205,208 | $96,733 | $205,208 | $96,733 |
| Total Debt (Long-term + Current) | $39,899 | $43,494 | $39,899 | $43,494 |
| Operating Cash Flow (6 Mo) | $109,718 | $78,222 | $109,718 | $78,222 |
Material Changes vs. Prior Period
- Profitability Surge: The company reported a significant turnaround from a net loss of $17.7M in Q2 2025 to a net income of $65.8M in Q2 2026. This was primarily driven by a $52.3M reduction in contract services expense due to a change in accounting estimate regarding arbitration fees.
- Revenue Decline: Total revenue decreased 13.6% year-over-year in Q2 2026 ($210.8M vs. $244.0M). The Hospital Division revenue dropped 14.6%, attributed to positive variable consideration adjustments realized in the prior year and lower revenue at same hospitals, despite a 9.6% increase in patient visits.
- Stock-Based Compensation: Stock-based compensation expense plummeted from $78.7M in Q2 2025 to $2.9M in Q2 2026. This decrease is due to the settlement of obligations for under-construction and ramping hospitals and a change in fair value estimates.
- Arbitration Cost Reduction: Effective June 30, 2026, the company amended its agreement with vendor HaloMD to a "pay-on-collected" basis and benefited from a CMS fee reduction (from $115 to $15 per dispute). These changes resulted in a $52.3M non-cash reduction to contract services expense.
Guidance, Outlook, and Risks
- Outlook: Management anticipates the arbitration fee changes will lead to an approximate 25-30% reduction in normalized historical contract services prospectively. The company expects continued volatility in quarterly results due to the subjective nature of revenue estimation under the IDR process.
- Capital Allocation: The company completed a $25.0M stock repurchase program (August 2025) and initiated a new $25.0M program (March 2026), with approximately $19.8M remaining as of June 30, 2026. Additionally, $25.3M was used to retire shares related to settlement agreements with former doctor owners.
- Key Risks:
- IDR Volatility: Revenue recognition is highly sensitive to arbitration outcomes and regulatory changes (e.g., "ghost rates" litigation, CMS fee rules).
- Legal Proceedings: Pending securities class action and derivative lawsuits allege misstatements regarding the IDR vendor and internal controls. Litigation regarding earn-out share calculations with former doctor owners (e.g., ABQ Plaintiffs) remains unresolved.
- Regulatory Uncertainty: Ongoing challenges to the No Surprises Act implementation and potential changes in federal/state reimbursement policies.
Investor Verification Checklist
- Arbitration Fee Impact: Verify the sustainability of the $52.3M expense reduction and the "pay-on-collected" fee structure with HaloMD.
- Revenue Quality: Assess the composition of revenue adjustments and the timing of IDR payments versus service delivery.
- Legal Exposure: Monitor the status of the securities class action (In re Nutex Health Inc. Securities Litigation) and the earn-out disputes with former hospital owners.
- Stock Dilution: Review the remaining obligations for shares issuable to former owners of under-construction hospitals and the impact of the $420.00 price floor.
- Liquidity: Confirm the $3.4M remaining availability on lines of credit and the company's ability to fund growth without additional capital raises.